Literature DB >> 32816988

Author Response: Pulmonary Vasodilators in Sarcoidosis-associated Pulmonary Hypertension.

Matthew Patel1,2, Karim Ladak1,2.   

Abstract

Entities:  

Keywords:  Pulmonary hypertension; Pulmonary vasodilators; Sarcoidosis

Mesh：

Substances：

Year:  2020        PMID： 32816988      PMCID： PMC7428212          DOI： 10.3121/cmr.2020.1600

Source DB:  PubMed          Journal:  Clin Med Res        ISSN： 1539-4182


× No keyword cloud information.
  14 in total

1.  Six-minute walk test and health status assessment in sarcoidosis.

Authors:  Robert P Baughman; Brian K Sparkman; Elyse E Lower
Journal:  Chest       Date:  2007-07       Impact factor: 9.410

2.  Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.

Authors:  Robert P Baughman; Daniel A Culver; Francis C Cordova; Maria Padilla; Kevin F Gibson; Elyse E Lower; Peter J Engel
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

3.  ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

Authors:  David B Badesch; Jeremy Feldman; Anne Keogh; Michael A Mathier; Ronald J Oudiz; Shelley Shapiro; Harrison W Farber; Michael McGoon; Adaani Frost; Martine Allard; Darrin Despain; Christopher Dufton; Lewis J Rubin
Journal:  Cardiovasc Ther       Date:  2011-06-20       Impact factor: 3.023

4.  Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?

Authors:  Nils Milman; Christopher M Burton; Martin Iversen; Regitze Videbaek; Claus V Jensen; Jørn Carlsen
Journal:  J Heart Lung Transplant       Date:  2008-03       Impact factor: 10.247

Review 5.  Pulmonary hypertension caused by sarcoidosis.

Authors:  Enrique Diaz-Guzman; Carol Farver; Joseph Parambil; Daniel A Culver
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

6.  Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Authors:  Paul M Hassoun; Roham T Zamanian; Rachel Damico; Noah Lechtzin; Rubina Khair; Todd M Kolb; Ryan J Tedford; Olivia L Hulme; Traci Housten; Chiara Pisanello; Takahiro Sato; Erica H Pullins; Celia P Corona-Villalobos; Stefan L Zimmerman; Mohamed A Gashouta; Omar A Minai; Fernando Torres; Reda E Girgis; Kelly Chin; Stephen C Mathai
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

7.  Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.

Authors:  Christopher F Barnett; Eric J Bonura; Steven D Nathan; Shahzad Ahmad; Oksana A Shlobin; Kwabena Osei; Ari L Zaiman; Paul M Hassoun; David R Moller; Scott D Barnett; Reda E Girgis
Journal:  Chest       Date:  2008-12-31       Impact factor: 9.410

Review 8.  Sarcoidosis-Associated Pulmonary Hypertension: An Updated Review and Discussion of the Clinical Conundrum.

Authors:  Adrian daSilva-deAbreu; Stacy A Mandras
Journal:  Curr Probl Cardiol       Date:  2019-11-30       Impact factor: 5.200

9.  Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

Authors:  Gregory John Keir; Simon L F Walsh; Michael A Gatzoulis; Philip S Marino; Konstantinos Dimopoulos; Rafael Alonso; Sergio Raposeiras-Roubin; Elisabetta A Renzoni; Toby M Maher; Athol U Wells; S John Wort
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-07-08       Impact factor: 0.670

Review 10.  Pulmonary hypertension complicating pulmonary sarcoidosis.

Authors:  M P Huitema; J C Grutters; B J W M Rensing; H J Reesink; M C Post
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.